Aclaris Therapeutics, Inc. (ACRS)
| Market Cap | 768.26M |
| Revenue (ttm) | 6.00M |
| Net Income (ttm) | -56.44M |
| Shares Out | 42.80M |
| EPS (ttm) | -1.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $18.04 |
| Previous Close | $17.97 |
| Change ($) | 0.07 |
| Change (%) | 0.39% |
| Day's Open | 18.16 |
| Day's Range | 17.15 - 19.50 |
| Day's Volume | 3,058,065 |
| 52-Week Range | 0.75 - 19.50 |
Aclaris (ACRS) posts favorable preliminary topline results from a phase IIa study evaluating its investigational oral candidate ATI-450 for treating moderate to severe rheumatoid arthritis. Sh...
WAYNE, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflam...
WAYNE, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-infla...
Investors are excited about the biotech's clinical trial results.
Aclaris Therapeutics stock triples after positive data on arthritis treatment
Aclaris Therapeutics (ACRS) stock is soaring higher on Tuesday after revealing results from a recent Phase 2a clinical trial. The post ACRS Stock Alert: Why Aclaris Therapeutics Is Up Over 200...
A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-base...
Aclaris Therapeutics Inc. (NASDAQ: ACRS) shares more than doubled to start out the week after the company announced positive results from its midstage rheumatoid arthritis (RA) study.
Investors need to pay close attention to Aclaris Therapeutics (ACRS) stock based on the movements in the options market lately.
WAYNE, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-infla...
WAYNE, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-infla...
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aclaris (ACRS) delivered earnings and revenue surprises of 13.79% and 1.61%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
WAYNE, Pa., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-infla...
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aclaris (ACRS) initiates a phase IIa study on ATI-1777, for the treatment of moderate-to-severe atopic dermatitis.
WAYNE, Pa., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-infla...
Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
WAYNE, Pa., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-in...
Aclaris (ACRS) delivered earnings and revenue surprises of 17.65% and 64.21%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
WAYNE, Pa., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inf...
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aclaris (ACRS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
WAYNE, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-...
Aclaris (ACRS) announces that it supports an IND application to evaluate its oral investigational MK2 inhibitor compound, ATI-450, in hospitalized patients with COVID-19.
Shares of micro-cap biopharma Aclaris Therapeutics Inc (NASDAQ: ACRS) were rallying Wednesday after the FDA gave its blessing for the company's investigational new drug application for a poten...
Aclaris Therapeutics Inc. (NASDAQ: ACRS) says it has received an update from the U.S.
WAYNE, Pa., June 17, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-...
WAYNE, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced tha...
As of late, it has definitely been a great time to be an investor Aclaris Therapeutics
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
WAYNE, Pa., March 31, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company, today announced that it has entered into a loan and secur...
Aclaris Therapeutics, Inc. (ACRS) CEO Neal Walker on Q4 2019 Results - Earnings Call Transcript
Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock ...
• Oral small molecule showed marked inhibition of TNFα, IL1β, IL8, and IL6 • Preliminary data support progression to Phase 2a Proof of Concept Trials in Immuno-Inflammatory Diseases
WAYNE, Pa., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced th...
Aclaris Therapeutics, Inc. (ACRS) CEO Neal Walker on Q3 2019 Results - Earnings Call Transcript
Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.
WAYNE, Pa., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it...
WAYNE, Pa., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, announced today th...
Top Ranked Momentum Stocks to Buy for October 3rd
Top Ranked Momentum Stocks to Buy for September 27th
As of late, it has definitely been a great time to be an investor in Aclaris Therapeutics, Inc. (ACRS).
Aclaris Therapeutics announced that it had achieved positive results in its Phase 3 THWART-2 study using A-101 45% topical solution to treat common warts.
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aclaris Therapeutics develops treatments for dermatological and immuno-inflammatory diseases.
WAYNE, Pa., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced i...
WAYNE, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases...
WAYNE, Pa., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases...
About ACRS
Aclaris Therapeutics, a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (... [Read more...]
| Industry Biotechnology | IPO Date Oct 7, 2015 |
| CEO Neal Walker | Employees 75 |
| Stock Exchange NASDAQ | Ticker Symbol ACRS |
Financial Performance
In 2019, ACRS's revenue was $4.23 million, a decrease of -31.28% compared to the previous year's $6.15 million. Losses were -$161.35 million, 21.6% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for ACRS stock is "Strong Buy." The 12-month stock price forecast is 20.00, which is an increase of 10.86% from the latest price.